Why choose the HepaRG™ cell model for NAFLD investigation?

Nonalcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease worldwide, is rapidly becoming the predominant cause of end-stage liver disease and a leading indication for liver transplantation.

HepaRG cell-based system is your top choice for steatosis studies. Among the few in vitro models proposed to mimic steatosis and its progression, the HepaRG cell model has been a suitable and robust model for steatosis induction and anti-steatotic drug screening.

Compared to other in vitro models, HepaRG™ cells show in response to free fatty acids supplements:

  • A higher lipid intracellular accumulation and ROS expression
  • Higher levels of secreted pro-inflammatory cytokines
  • Greater sensitivity to drug-induced steatosis

Not enough to shift toward HepaRG-cell-based systems? Find more good reasons to start your steatosis study on the HepaRG™ cell line on the SaferWorldbyDesign platform. 


SaferWorldbyDesign integrates in silico and in vitro methods to develop standard and premium Integrated Approaches to Testing and Assessment (IATAs), including methods that support ingredient and formulation screening and testing, product design and the preparation of Regulatory Dossiers.


Edelweiss Connect GmbH is registered as a limited company with Handelsregisteramt of Kanton Basel-Stadt

Swiss ID (UID) number: CHE-114.414.615

Copyright | SaferWorldbyDesign 2023